Congress of the European Society for Sexual Medicine edition:15 location:Amsterdam date:6-9 December 2012
To study the improvement of erection in men with severe erectile dysfunction (ED), which were not satisfied with the highest dose of a short term PDE-5-Inhibitor (S-PDE-5-I), by adding a long term PDE-5-Inhibitor (L-PDE-5-I) in a daily dose.
This observational open-label uncontrolled study enrolled 128 men (aged 52 to 78 years), in whom 2 months of S-PDE-5-I therapy at the maximal recommended dose with at least four attempts at intercourse during the 2-month period had failed. To assess sexual function: the Erection Hardness Score (evaluated by the patient as well as the partner and physician too), IIEF questionnaire and several questionnaires completed by the patient and the patients' partner were used.
169 men and their partners completed the baseline questionnaires after the S-PDE-5-I therapy period and gave consent . The mean ± SD baseline EHS (range 1–4) was 2.3±0.8 (self-assessed), 2.2±0.9 (partner-assessed), and 2.2±0.8 (physician-assessed). 128 patients and their partners returned within the 2–4 month follow-up period. The assessment follow-up showed an increase in the mean values of all the four domains of IIEF. According to several general assessment questions, satisfaction and confidence improved. Partners found that erectile capacity had greatly improved from baseline to study end. No major adverse effects were observed.
The results of this study support the use of a combination of a S-PDE-5 I and a L-PDE-5-I in men in whom a S-PDE-5-I alone fails. We suggest that every man, who is not totally satisfied with PDE-5-I treatment, could benefit from a combination of a long- and short-term PDE-5-Inhibitor